← Back

Shandong Intco Medical Products Co Ltd

Intco Medical Technology Co., Ltd. engages in the research and development, production, and marketing of medical consumables, rehabilitation equipment, and physiotherapy care for medical and elderly care institutions, household daily use, and other related industries in China and internationally. The company offers disposable gloves, gowns, apparel, face masks, diaper, pad, wipes, non-woven sundries, PE products, and hand hygiene; wheelchair, scooter, rollator, lift, and others; physical therapy hot and cold therapy, sport and outdoor, pet products, patient monitoring, and electrosurgery. It also provides ECG electrode, such as monitoring ECG, stress test and holter, diagnostic ECG, pre-wired neonatal, repositionable, tens, off-set ECG, and defibrillation electrode; grounding pad, electrosurgical pencil, and feminine care. The company was formerly known as Intco Medical Technology Co., Ltd. and changed its name to Intco Medical Technology Co., Ltd. in January 2020. Intco Medical Technology Co., Ltd. was founded in 2009 and is headquartered in Zibo, China.

Price · split & dividend adjusted
News & notes moving 300677.CS
300677.CS

Tiantong Corporation boosts investment in new soft magnetic materials, Zhonghong Medical net profit surges 2662%

Tiantong Corporation plans to invest 434 million yuan through a wholly-owned subsidiary to build an intelligent manufacturing project with an annual output of 14,600 tonnes of high-end soft magnetic new materials, with a construction period of about 36 months. Zhonghong Medical's net profit attributable to the parent company in the first half of the year surged 2662.38% year-on-year to 159 million yuan. In addition, several companies released half-year reports, with Hangzhou Cable, Yahua Group, and Yongtai Technology all posting substantial net profit growth. Jingsheng Co.'s self-developed large-size CVD SiC chemical vapour deposition coating complete equipment has passed factory inspection and been delivered to customers. Sino Medical's H-share issuance is being filed with the China Securities Regulatory Commission and is expected to be completed in the first quarter of next year; its HT Supreme drug-eluting stent system has been approved in Paraguay. Institutional seats made net purchases of 656 million yuan in Hengtong Optic-Electric and 168 million yuan in Yangtze Optical Fibre and Cable. Wanxun Automation has made progress in its domestic and overseas semiconductor business layout, and Shandong Haode and Anhui Kaize, controlled by Intco Medical, delivered excellent second-quarter profits.
上海证券报·1dRead more ▾
300677.CS2

Intco Medical Says Customers Show Strong Willingness to Place Orders

Intco Medical stated during its semi-annual report conference call that customers currently show a strong willingness to place orders. In the second quarter, affected by the situation in the Middle East and fluctuations in crude oil prices, the price of disposable gloves rose significantly. Coupled with rising international shipping costs, customers slowed down procurement and consumed inventory, resulting in customer inventories currently being almost all at low levels, with obvious restocking demand. After August, the peak purchasing season for customers will begin and is expected to last until around Christmas.
证券时报·2dRead more ▾
300677.CS2

Intco Medical's first-half net profit rises 17.86%, plans dividend of 1 yuan per 10 shares

Intco Medical disclosed its 2026 semi-annual report. In the first half of the year, it achieved operating revenue of 6.909 billion yuan, up 40.61% year on year. Net profit attributable to shareholders of the listed company was 837 million yuan, up 17.86% year on year. Basic earnings per share were 1.31 yuan. The company also plans to distribute a cash dividend of 1.0 yuan per 10 shares before tax. Since the second quarter, international oil prices have fluctuated upward, compounded by the impact of the Middle East situation. Prices of upstream raw materials such as nitrile latex have risen sharply, significantly lifting industry costs. However, benefiting from improved supply-demand dynamics and cost-side support, selling prices of disposable gloves orders have risen in tandem, and the industry's profit margin has continued to widen. The overall picture shows both volume and price rising, with thicker profits. As of the end of the reporting period, the company's annualized production capacity for disposable non-latex gloves reached 107 billion gloves, including annualized capacity of 74 billion for disposable nitrile gloves and 33 billion for disposable PVC gloves.
证券时报·3dRead more ▾
300677.CS

Disposable glove makers rally as Zhonghong Medical forecasts up to 35-fold profit surge

On July 29, shares of disposable glove producers Zhonghong Medical, Intco Medical, and Blue Sail Medical rose across the board, with Zhonghong Medical hitting its daily limit up. The previous evening, Zhonghong Medical issued a profit forecast, estimating net profit attributable to shareholders of the listed company at 140 million to 210 million yuan for the first half of this year, a year-on-year increase of 23.38 to 35.57 times, mainly driven by higher selling prices for health protection gloves, improved product gross margins, and stronger cost control. Blue Sail Medical had earlier forecast first-half net profit of approximately 90 million to 110 million yuan, swinging from a loss to a profit year-on-year, with its health protection division achieving net profit of 250 million to 300 million yuan and operating revenue up about 36 percent year-on-year. This year, rising international oil prices have pushed up raw material costs for nitrile gloves, but Chinese manufacturers, with their complete petrochemical supply chains, have achieved raw material self-sufficiency and a significant cost advantage, allowing them to capture excess profits during the industry's price hike cycle.
第一财经·29dRead more ▾
300677.CS2

Intco Medical's Controlling Shareholder Liu Fangyi Releases Pledge on 1.25 Million Shares

Intco Medical's controlling shareholder Liu Fangyi recently completed the release of pledge on 1.25 million company shares, representing 0.54% of his total holdings and 0.19% of the company's total share capital. As of the announcement date, Liu Fangyi has a cumulative pledged amount of 26.75 million shares, accounting for 11.54% of his holdings and 4.09% of the company's total share capital.
北京商报·55dRead more ▾